SuperSonic Imagine Highlights the Clinical Benefits of Real-Time ShearWave(TM) Elastography in the Middle East

AIX-EN-PROVENCE, FRANCE--(Marketwired - Jan 30, 2017) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today its participation in the Arab Health Show, January 30 - February 2, in Dubai, to demonstrate the clinical benefits of ShearWave™ Elastography (SWE™) in assessing major diseases such as chronic liver disease, cancer of the breast, prostate and thyroid, and in the domain of musculoskeletal imaging.

SuperSonic Imagine's Aixplorer®, is the only ultrasound system available to deliver shear wave elasticity imaging (SWE™) in real-time in a large anatomic region of interest. SWE is a quick, non-invasive exam that provides color coded maps and quantitative measurement of tissue stiffness. This information is used by physicians to help identify potentially malignant or other diseased tissue. As of today, over 300 peer-reviewed articles have demonstrated the clinical benefits of SWE in a wide range of clinical applications.

Liver diseases, such as chronic hepatitis B, chronic hepatitis C and nonalcoholic fatty liver disease (NAFLD), have become a serious health issue for the Middle Eastern population. The World Health Organization estimates that there are at least 21.3 million hepatitis C virus (HCV) carriers in the Eastern Mediterranean countries, which is close to the number of carriers estimated in the Americas and Europe combined.¹

To date, over 100 publications have demonstrated the reliability and effectiveness of SWE to assess chronic liver disease including hepatitis B, C and NAFLD. Liver biopsy has traditionally been considered the standard for assessing liver fibrosis but this invasive method has major drawbacks, including significant incidence of morbidity, procedure and hospitalization costs, and clinical shortcomings^2-3.

"The Middle East has become a strategic territory and we are seeing a rapidly growing interest in our Aixplorer ultrasound system, particularly for its ability to non-invasively and in less than 60 seconds assess liver fibrosis and improve lesions diagnosis. We have strengthened our distributor network and we believe that the proven clinical benefits of our technology will position SuperSonic Imagine as a major player of ultrasound imaging in this market," explains Jacques Souquet, Founder and Chief Innovation Officer of SuperSonic Imagine.